^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)

    i
    Other names: NTRK3, TRKC, Neurotrophic tyrosine kinase, receptor, type 3
    6d
    Combining multi-omics analysis and network toxicology to explore the role and underlying mechanisms of an environmental pollutant in gastric cancer: A study of Diisononyl Phthalate. (PubMed, Ecotoxicol Environ Saf)
    Molecular docking suggested that DINP can potentially interact with key targets, especially MAPK14 and FAAH. Our findings suggest that DINP may promote GC development through interactions with core targets like MAPK14, highlighting its potential role as an environmental risk factor and a candidate biomarker.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • MAPK14 (Mitogen-Activated Protein Kinase 14)
    7d
    Metastatic and recurrent salivary gland carcinoma: clinical characteristics and comprehensive molecular profiling at a tertiary care center. (PubMed, J Cancer Res Clin Oncol)
    The impact of immunohistochemical or molecular markers on treatment selection and response was most pronounced in SDC. HER2 IHC2 + expression was observed across multiple subtypes, indicating that TDxd may represent a potential treatment option for more pts than previously anticipated. The impact of comprehensive genomic profiling on targeted treatment options is currently still modest.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
    |
    HER-2 amplification • HER-2 expression
    |
    Vitrakvi (larotrectinib) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    13d
    AB-106-C205: Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion (clinicaltrials.gov)
    P2, N=14, Terminated, Nuvation Bio Inc. | N=40 --> 14 | Recruiting --> Terminated; The study was discontinued early by the Sponsor for business reasons on 06 Dec 2024
    Enrollment change • Trial termination • Pan tumor
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    Ibtrozi (taletrectinib)
    14d
    KIT Mutation-NTRK fusion oncogenic driver switch: a novel mechanism of acquired imatinib resistance in GIST. (PubMed, NPJ Precis Oncol)
    In vitro modeling demonstrated that EML4::NTRK3 confers imatinib resistance, while sensitizing GIST cells to NTRK inhibitors. This first reported instance of an NTRK fusion as a secondary event in GIST progression underscores the importance of testing for NTRK alterations in tumors that have developed resistance to tyrosine kinase inhibitors to ensure patients are offered all available therapeutic options.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NTRK (Neurotrophic receptor tyrosine kinase) • ANO1 (Anoctamin 1)
    |
    KIT mutation • PDGFRA mutation • KIT expression • NTRK fusion
    |
    imatinib
    17d
    A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers. (PubMed, ESMO Open)
    Our data support the clinical implementation of a tailored, histology-driven MP algorithm, potentially optimizing the genomic testing resources in SGCs.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • AR (Androgen receptor) • HRAS (Harvey rat sarcoma viral oncogene homolog) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase) • MYBL1 (MYB Proto-Oncogene Like 1)
    |
    HER-2 positive • HER-2 negative
    25d
    STARTRK-2: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (clinicaltrials.gov)
    P2, N=534, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date • Pan tumor
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    ALK rearrangement • ROS1 rearrangement
    |
    Xalkori (crizotinib) • Rozlytrek (entrectinib)
    25d
    DNA And RNA-Based Next-Generation Sequencing For Companion Diagnostic Rearrangement Detection In Solid Tumors. (PubMed, Oncologist)
    A higher rate of CDx SV detection-most significantly for NRG1 and NTRK fusions-was observed using concurrent DNA-CGP and RNA-CGP compared to DNA-CGP alone. Our results highlight the complementary nature of these methods. Given the substantial clinical benefit of SV targeted therapies, an integrated DNA/RNA profiling strategy should be part of routine clinical care.
    Journal • Next-generation sequencing • Companion diagnostic
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NRG1 (Neuregulin 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NRG1 fusion • NTRK fusion
    26d
    Successful treatment of pediatric scalp mesenchymal tumor with NTRK rearrangement: a case report. (PubMed, Transl Pediatr)
    According to our research, this case represents the first reported successful surgical resection of a pediatric scalp tumor with NTRK rearrangement. This finding suggests that clinicians should pay attention to early diagnosis through molecular testing and recognize the feasible value of surgical resection in the treatment of this type of tumor.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK positive
    |
    VENTANA pan-TRK (EPR17341) Assay
    27d
    2021-ky301: Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=78, Completed, Anhui Provincial Hospital | Recruiting --> Completed
    Trial completion
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    BRAF V600E • KRAS G12C • BRAF V600 • MET exon 14 mutation • KRAS G12
    27d
    THE INFLUENCE OF AGE-INDEPENDENT SOMATIC DRIVER ALTERATIONS ON CLINICAL OUTCOMES IN PEDIATRIC AND YOUNG ADULT THYROID CANCER. (PubMed, Eur Thyroid J)
    While prognosis steadily improved with age, mutation status remained the dominant factor determining outcomes. Somatic drivers offer prognostic insights independent of age in paediatric and young adult DTC, establishing a molecular framework for precision risk stratification that complements traditional clinical staging and age-based assessments.
    Clinical data • Journal
    |
    BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • RAS (Rat Sarcoma Virus) • DICER1 (Dicer 1 Ribonuclease III)
    |
    BRAF V600E • BRAF V600 • RET fusion • RAS mutation
    1m
    Secretory carcinoma of the lacrimal gland (PubMed, J Fr Ophtalmol)
    The characterization of histological subtypes of carcinomas has direct implication in the therapeutic approach with the use of targeted therapies. Thus, tyrosine kinase inhibitors can provide valuable options in the treatment of secretory carcinomas.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
    2ms
    ETV6-NTRK3 positive mammary analogue secretory carcinoma of the salivary gland: A case report and literature review. (PubMed, J Pak Med Assoc)
    Immunohistochemistry and genetic analysis are important tools to differentiate MASC from its morphological mimickers. The treatment approach for MASC has not been well defined or standardised, necessitating further studies to develop evidence-based guidelines.
    Review • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase) • TFAM (Transcription Factor A, Mitochondrial)
    |
    NTRK positive